AI assistant
SCIDEV LTD — Regulatory Filings 2018
Sep 19, 2018
65761_rns_2018-09-19_948358e0-c9db-4c16-982f-3fb2daf06eac.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
==> picture [277 x 72] intentionally omitted <==
Suite 105 48 Atchison Street St Leonards NSW 2065 Australia ABN 25 001 150 849
Phone: 61 0428 002 590 Email: [email protected] Website: www.scidev.com.au ASX code: SDV
Companies Announcements Office Australian Stock Exchange
20 September 2018
SciDev Receives First United States Purchase Order
-
Purchase order for chemical supply received from Peabody Energy in the United States
-
Validates Company strategy of targeting expansion through foundation customer groups
-
MOU partner, Phoenix Process Equipment Co. to support SciDev with ongoing US sales initiatives
SciDev Ltd (ASX: SDV) (‘SciDev’ or ‘the Company’) is pleased to advise that it has received its first United States chemical order from existing customer, Peabody Energy.
The initial order, which is for the Company’s coagulant product, will be utilised at a thermal coal site in the United States on a trial basis. Following a successful trial period, SciDev expects to receive additional and ongoing orders from Peabody Energy.
The order is validation of the SciDev’s strategy of expansion through foundation customer groups. Peabody Energy has been a longstanding client of the Company, utilising an OptiFlox System® at the 12MTPA Wilpingjong thermal coal mine in New South Wales (refer ASX announcement: 16 March 2017).
SciDev has also recently received a purchase order from Peabody Energy for an OptiFlox System®, which will be trialled at a coking coal site in the Bowen Basin (refer ASX announcement: 16 July 2018). The Company expects this system to be commissioned in the near term.
Further, the Company wishes to advise that the OptiFlox System® deployed to a major coking coal producer in the Bowen Basin (refer ASX announcement: 11 July 2018) is due to be commissioned in the coming weeks.
The Board and management look forward to updating shareholders on these trials and other pending developments in the near term.
Kieran Rodgers
Managing Director
Released through: Henry Jordan, Six Degrees Investor Relations +61 431 271 538